Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

The HUMANOID Center at UC San Diego is pioneering organoid research aimed at improving the reliability and reproducibility of ...

Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Q4 2024 Earnings Call Transcript January 31, 2025 AbbVie Inc. misses on earnings expectations. Reported EPS is $2.16 EPS, expectations were $2.98. Operator: Good morning and thank you for standing by.

The current number of monogenic IBD disorders continues to grow with genes classified into six categories according to the biologic ... therapy for IBD. These results suggested that this heterozygote ...

40 Additionally, it is essential to profile transcriptomics, metatranscriptomics and biological processes through functional ... In addition to the animal model limitations, most studies on phage ...

Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, while foods high in insoluble fiber, processed meat, spicy foods, dairy, and ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

Patients with ankylosing spondylitis and IBD exhibit distinct clinical and radiographic features, compared against those without comorbid IBD.

Combination Therapy May ... of inflammation in IBD. The second is that anti-TNF monotherapy is more commonly associated with development of antibodies to the anti-TNF biologic.

Omvoh has additional ongoing trials in Crohn's disease and UC, including studies to evaluate the long-term efficacy and safety of Omvoh in pediatric patients and adults, and a Phase 4 real-world ...